CR20240462A - Anticuerpos biespecíficos que comprenden un dominio de unión a nrp1 y métodos de uso de los mismos - Google Patents

Anticuerpos biespecíficos que comprenden un dominio de unión a nrp1 y métodos de uso de los mismos

Info

Publication number
CR20240462A
CR20240462A CR20240462A CR20240462A CR20240462A CR 20240462 A CR20240462 A CR 20240462A CR 20240462 A CR20240462 A CR 20240462A CR 20240462 A CR20240462 A CR 20240462A CR 20240462 A CR20240462 A CR 20240462A
Authority
CR
Costa Rica
Prior art keywords
binding domain
bispecific antibodies
methods
nrp1
antibodies
Prior art date
Application number
CR20240462A
Other languages
English (en)
Spanish (es)
Inventor
Ho-Juhn Song
Original Assignee
Pinetree Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pinetree Therapeutics Inc filed Critical Pinetree Therapeutics Inc
Publication of CR20240462A publication Critical patent/CR20240462A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CR20240462A 2022-03-30 2023-03-30 Anticuerpos biespecíficos que comprenden un dominio de unión a nrp1 y métodos de uso de los mismos CR20240462A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263325312P 2022-03-30 2022-03-30
US202263325317P 2022-03-30 2022-03-30
PCT/US2023/016963 WO2023192514A1 (en) 2022-03-30 2023-03-30 Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof

Publications (1)

Publication Number Publication Date
CR20240462A true CR20240462A (es) 2024-12-11

Family

ID=86184900

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20240462A CR20240462A (es) 2022-03-30 2023-03-30 Anticuerpos biespecíficos que comprenden un dominio de unión a nrp1 y métodos de uso de los mismos

Country Status (13)

Country Link
US (1) US20240101682A1 (https=)
EP (1) EP4499696A1 (https=)
JP (1) JP2025511135A (https=)
KR (1) KR20240163751A (https=)
CN (1) CN119403831A (https=)
AU (1) AU2023245728A1 (https=)
CA (1) CA3255754A1 (https=)
CL (1) CL2024002899A1 (https=)
CO (1) CO2024014799A2 (https=)
CR (1) CR20240462A (https=)
IL (1) IL315960A (https=)
MX (1) MX2024011978A (https=)
WO (1) WO2023192514A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL318499A (en) * 2022-07-30 2025-03-01 Pinetree Therapeutics Inc Compounds for targeted lysosomal degradation and methods of using them
AU2023378712A1 (en) * 2022-11-07 2025-05-01 Pinetree Therapeutics, Inc. Combination therapy comprising bispecific antibodies comprising an nrp1 binding domain

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA96139C2 (uk) * 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
WO2017171373A2 (ko) * 2016-03-29 2017-10-05 아주대학교산학협력단 Egfr 표적 제제에 대한 저항성을 억제하기 위한 조성물
KR102048474B1 (ko) * 2016-03-29 2019-11-26 아주대학교산학협력단 Egfr 표적 제제에 대한 저항성을 억제하기 위한 조성물
CA3060190A1 (en) * 2017-04-24 2018-11-01 Ichnos Sciences SA T cell redirecting bispecific antibodies for the treatment of egfr positive cancers
WO2020027224A1 (ja) * 2018-07-31 2020-02-06 国立大学法人東京大学 新たな結合特異性を抗体に付与する超汎用法
WO2020079280A1 (en) * 2018-10-19 2020-04-23 Ichnos Sciences SA T cell redirecting bispecific antibodies for the treatment of squamous cell cancers

Also Published As

Publication number Publication date
KR20240163751A (ko) 2024-11-19
CL2024002899A1 (es) 2025-02-07
US20240101682A1 (en) 2024-03-28
CA3255754A1 (en) 2023-10-05
JP2025511135A (ja) 2025-04-15
EP4499696A1 (en) 2025-02-05
AU2023245728A1 (en) 2024-09-26
WO2023192514A1 (en) 2023-10-05
CO2024014799A2 (es) 2024-11-18
IL315960A (en) 2024-11-01
CN119403831A (zh) 2025-02-07
MX2024011978A (es) 2025-02-10

Similar Documents

Publication Publication Date Title
MX2023010499A (es) Anticuerpos heterodimericos que se unen a cd3 y cldn6.
ZA202206437B (en) Claudin18.2 binding moieties and uses thereof
PH12021551500A1 (en) Anti-ctla4 antibodies and methods of use thereof
MX2023004349A (es) Anticuerpos monoclonales anti-ccr8 y sus usos.
AU2019415848A8 (en) Claudin18.2 binding moieties and uses thereof
CR20240462A (es) Anticuerpos biespecíficos que comprenden un dominio de unión a nrp1 y métodos de uso de los mismos
PH12022550195A1 (en) Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
EP4249068A3 (en) Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
MX2016015389A (es) Anticuerpos que se enlazan a cd3 epsilon humano y de mono cinomolgo.
WO2022082073A3 (en) Compositions and methods for muc18 targeting
NZ785401A (en) Anti-ms4a4a antibodies and methods of use thereof
MX2022013876A (es) Constructos de anticuerpos triespecificos precursores y metodos de uso de los mismos.
PH12022551398A1 (en) Anti-mertk antibodies and methods of use thereof
WO2021262597A3 (en) Lair-1-binding agents and methods of use thereof
PE20231573A1 (es) Anticuerpos biespecificos cd47-cd38
PH12020551323A1 (en) Anti cd6 antibodies for treating severe asthma
MX2025000124A (es) Combinaciones de proteinas de fusion a fc heterodimericas il15/il15r alfa y anticuerpos biespecificos fcrh5xcd3 para el tratamiento de tipos de cancer de sangre
MX2025000053A (es) Anticuerpos monoclonales anti-slc34a2 y sus usos
MX2023006650A (es) Anticuerpos multiespecificos y combinaciones de anticuerpos.
MX2024002961A (es) Anticuerpo y uso del mismo.
MX2024015238A (es) Anticuerpos igf1r
MY207830A (en) Antigen binding proteins
WO2021030484A4 (en) Il1rap antibodies
BR112022002761A2 (pt) Proteínas de ligação a 4-1bb e ox40 e composições e métodos relacionados, anticorpos contra 4-1bb, anticorpos contra ox40
PH12021500023A1 (en) Bi-specific binding agents targeting syndecan-1 and fibroblast growth factor receptor